PMID- 22436722
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20120322
IS  - 1556-9845 (Print)
IS  - 1556-9845 (Linking)
VI  - 3
IP  - 1
DP  - 2008 Jan
TI  - Efficacy of intramyocardial injection of angiogenic cell precursors for ischemic 
      cardiomyopathy: a case match study.
PG  - 38-45
LID - 10.1097/IMI.0b013e31816755dd [doi]
AB  - INTRODUCTION: : The objective of this study is to determine the efficacy of 
      intramyocardial angiogenic cell precursors (ACPs) injection in ischemic 
      cardiomyopathy (ICM). METHODS: : Twenty-five ICM patients (cell group) underwent 
      intramyocardial ACPs injection. Seventeen ICM patients (control group) treated by 
      medical means were matched with cell group. There was no statistically 
      significant difference between cell and control groups in relation to left 
      ventricular ejection fraction (LVEF) and comorbidities. In the cell group, mean 
      age was 58.4 +/- 13.7 years. Mean LVEF was 26.1% +/- 7.4%. New York Heart Association 
      (NYHA) class was 2.9 +/- 0.6. The ACPs were derived and expanded from autologous 
      blood. The number of cells before injection was 27.4 +/- 18.8 million cells. The 
      cells were injected into the nonviable myocardium and hypokinetic segments in the 
      cell group. RESULTS: : There was no new ventricular arrhythmia. NYHA was improved 
      by 0.9 +/- 1.0 (P < 0.001) at 229.9 +/- 98.8 days. Six-minute walk test and quality 
      of life assessed by short form-36 improved in the cell group. LVEF was improved 
      in 72% of patients (18 of 25). LVEF improved by 6.4 +/- 9.9 points % (P = 0.003) at 
      290.4 +/- 210.3 days. The percentage of infarction area decreased 21.9 +/- 17.4 
      points % at 159 +/- 54 days postoperatively. There was no significant improvement 
      of NYHA and LVEF in the control group. CONCLUSIONS: : For this efficacy study, 
      the NYHA class, quality of life, and six-minute walk test were improved after 
      cell transplantation. The LVEF was also significantly improved in the cell 
      treated group.
FAU - Arom, Kitipan V
AU  - Arom KV
AD  - From the Division of Cardiovascular Surgery, Bangkok Heart Hospital, Bangkok, 
      Thailand.
FAU - Ruengsakulrach, Permyos
AU  - Ruengsakulrach P
FAU - Jotisakulratana, Vibul
AU  - Jotisakulratana V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Innovations (Phila)
JT  - Innovations (Philadelphia, Pa.)
JID - 101257528
EDAT- 2008/01/01 00:00
MHDA- 2008/01/01 00:01
CRDT- 2012/03/23 06:00
PHST- 2012/03/23 06:00 [entrez]
PHST- 2008/01/01 00:00 [pubmed]
PHST- 2008/01/01 00:01 [medline]
AID - 01243895-200801000-00009 [pii]
AID - 10.1097/IMI.0b013e31816755dd [doi]
PST - ppublish
SO  - Innovations (Phila). 2008 Jan;3(1):38-45. doi: 10.1097/IMI.0b013e31816755dd.